Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Propranolol Antitrust Litigation
Case Number:
1:16-cv-09901
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Gibson Dunn
- Girard Sharp
- Hagens Berman
- Kaplan Fox
- Kasowitz Benson
- Kirkland & Ellis
- Latham & Watkins
- Lieff Cabraser
- Morgan Lewis
- Nussbaum Law Group
- O'Melveny & Myers
- Safirstein Law
- Saxena White
- Williams & Connolly
- Wilson Sonsini
Companies
- Allergan PLC
- American Federation of State County & Municipal Employees
- Avet Pharmaceuticals Inc.
- Endo International PLC
- Par Pharmaceutical Cos. Inc.
- Teva Pharmaceutical Industries Ltd.
- Upsher-Smith Laboratories Inc.
- Viatris Inc.
Sectors & Industries:
-
April 07, 2017
Teva, Others Must Face Blood Pressure Drug Antitrust Suit
Teva, Mylan, Heritage Pharmaceuticals and other generic-drug manufacturers can't dodge antitrust claims accusing them of conspiring to massively increase the price of propranolol hydrochloride, a generic blood pressure medication, a New York federal judge said Thursday.
-
March 13, 2017
Pharma Cos. Seek To Toss Blood Pressure Drug Antitrust Suit
Mylan, Teva Pharmaceuticals and other generic-drug manufacturers on Friday slammed antitrust claims brought by drug buyers in New York federal court over an alleged conspiracy to jack up the price of generic blood pressure medication propranolol, arguing that the buyers haven't plausibly shown there was a price-fixing conspiracy.